Moderna, Inc. $MRNA Shares Sold by Public Employees Retirement System of Ohio

Key Points

• The Public Employees Retirement System of Ohio reduced its holdings in Moderna, Inc. by 17.1% during the 2nd quarter, owning 110,125 shares valued at $3,038,000.
• Moderna's latest earnings report showed an EPS of ($2.13), exceeding analysts' expectations, though revenue fell 41.1% year-over-year.
• Institutional investors now own 75.33% of Moderna's shares, with multiple firms acquiring new stakes recently, indicating shifting investor interest.

Public Employees Retirement System of Ohio decreased its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 17.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 110,125 shares of the company's stock after selling 22,775 shares during the quarter. Public Employees Retirement System of Ohio's holdings in Moderna were worth $3,038,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. S Bank Fund Management Ltd acquired a new stake in Moderna in the first quarter valued at approximately $25,000. SVB Wealth LLC acquired a new stake in Moderna in the first quarter valued at approximately $28,000. CX Institutional grew its position in shares of Moderna by 1,129.8% during the second quarter. CX Institutional now owns 1,033 shares of the company's stock worth $29,000 after buying an additional 949 shares in the last quarter. Costello Asset Management INC acquired a new stake in shares of Moderna during the first quarter worth approximately $30,000. Finally, Sentry Investment Management LLC acquired a new stake in shares of Moderna during the first quarter worth approximately $31,000. Institutional investors and hedge funds own 75.33% of the company's stock.

Moderna Price Performance

Shares of MRNA opened at $27.60 on Thursday. The business's fifty day moving average price is $26.52 and its 200 day moving average price is $27.49. Moderna, Inc. has a 12-month low of $23.15 and a 12-month high of $63.69. The stock has a market capitalization of $10.74 billion, a PE ratio of -3.67 and a beta of 2.01.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.99) by $0.86. The company had revenue of $142.00 million for the quarter, compared to analysts' expectations of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The firm's quarterly revenue was down 41.1% compared to the same quarter last year. During the same period last year, the business posted ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

MRNA has been the subject of a number of recent analyst reports. Cowen initiated coverage on shares of Moderna in a research report on Sunday, July 13th. They set a "hold" rating for the company. Leerink Partners decreased their price target on shares of Moderna from $18.00 to $15.00 and set an "underperform" rating for the company in a research report on Friday, August 22nd. JPMorgan Chase & Co. set a $26.00 price target on shares of Moderna in a research report on Friday, August 1st. Wells Fargo & Company reissued an "equal weight" rating on shares of Moderna in a research report on Sunday, July 13th. Finally, Barclays decreased their price target on shares of Moderna from $40.00 to $31.00 and set an "equal weight" rating for the company in a research report on Monday, August 4th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, fourteen have given a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $41.81.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.